170
Participants
Start Date
July 31, 2002
Study Completion Date
July 31, 2004
Tolvaptan
St. Luke's-Roosevelt Hospital Center, New York
South Bay Cardiovascular Associates, West Islip
Guthrie Clinic, LTD, Sayre
Medical College of Pennsylvania, Philadelphia
Ralph H. Johnson VAMC, Charleston
Georgia Heart Specialists, Covington
Cardiovascular Associates of Augusta, PA, Augusta
Cardiovascular Research Center of South Florida, Miami
Cardiology Associates of Fort Lauderdale, Fort Lauderdale
The Heart and Vascular Institute of Florida, St. Petersburg
Charlotte Heart Group, Port Charlotte
Stern Cardiovascular Center, Memphis
Midwest Cardiology Research Foundation, Columbus
North Ohio Research LTD, Lorraine
North Ohio Research LTD., Sandusky
The Lindner Clinical Trial Center, Cincinnati
The Care Group, LLC, Indianapolis
Harper Hospital/Wayne State University, Detroit
John Dingell VA Medical Center, Detroit
Illinois Heart and Lung Associates, SC, Normal
Medical Research Institute, Slidell
Arkansas Heart, Little Rock
University of Colorado, Denver
Desert Cardiology of Tucson, Tucson
San Diego Cardiac Center, San Diego
Cardiovascular Consultants Medical Group, Inc., Walnut Creek
Northern California Medical Associates, Santa Rosa
The Hoffman Heart Institute of CT/St. Francis Hospital, Hartford
Yale University, New Haven
Androscoggin Cardiology Associates, Auburn
Maine Cardiology Associates, Portland
Pentucket Medical Associates, Haverhill
Mystic Cardiology Associates, Inc., Medford
Miriam Hospital, Providence
University Cardiology Foundation, Providence
Health Sciences Center, Winnipeg
Health Sciences Center Memorial University of Newfoundland, St. John's
London Health Sciences Center, London
St. Michael's Hospital, Toronto
The Toronto Hospital, Toronto
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY